Astrazeneca Expands AI Partnership With Owkin Under Three-Year Licensing Deal
13 maj, 13:16
13 maj, 13:16
07:16 AM EDT, 05/13/2026 (MT Newswires) -- Astrazeneca (AZN) signed a three-year licensing agreement with Owkin to develop biopharma AI agents using Owkin's K Pro platform for drug development and decision-making, Owkin said Wednesday.
Under the agreement, Owkin said it will develop and deploy AI agents within AstraZeneca's IT systems and workflows to support competitive intelligence and data-driven decision making across the biopharma value chain.
13 maj, 13:16
07:16 AM EDT, 05/13/2026 (MT Newswires) -- Astrazeneca (AZN) signed a three-year licensing agreement with Owkin to develop biopharma AI agents using Owkin's K Pro platform for drug development and decision-making, Owkin said Wednesday.
Under the agreement, Owkin said it will develop and deploy AI agents within AstraZeneca's IT systems and workflows to support competitive intelligence and data-driven decision making across the biopharma value chain.
Evolution
Evolution
1 DAG %
Senast
OMX Stockholm 30
0,74%
(13:49)
Intrum
Idag, 10:19
Intrums aktie klättrar efter köpråd
OMX Stockholm 30
1 DAG %
Senast
3 077,98